Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Proper expression of the glucocorticoid receptor (GR) plays an essential role in the development of the lung. GR expression and signalling in the lung is manipulated by administration of synthetic glucocorticoids (Gcs) for the treatment of neonatal, childhood and adult lung diseases. In lung cancers, Gcs are also commonly used as co-treatment during chemotherapy. This review summarises the effect of Gc monotherapy and co-therapy on lung cancers in vitro, in mouse models of lung cancer, in xenograft, ex vivo and in vivo The disparity between the effects of pre-clinical and in vivo Gc therapy is commented on in light of the recent discovery of GR as a novel tumour suppressor gene.

Original publication

DOI

10.1530/JOE-15-0496

Type

Journal article

Journal

J Endocrinol

Publication Date

04/2016

Volume

229

Pages

R17 - R28

Keywords

chemotherapy, glucocortiocoid receptor, lung cancer, tumour suppressor, Animals, Glucocorticoids, Humans, Lung, Lung Neoplasms, Receptors, Glucocorticoid